Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Stand-ready manufacturing revenue by Quarter
Stand-ready manufacturing revenue (sovereign mRNA facilities in U.K., Canada & Australia) ($M) ($M)
Moderna Stand-ready manufacturing revenue: $31M in Q2 2026, up 82.4% from a year earlier.
Latest, Q2 2026
31
Period ended Jun 30, 2026
Change on a year earlier
+82.4%
17 in Q2 2025
History
4 quarters
Since Q1 2025
Sources
2
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Revenue).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stand-ready manufacturing revenue (sovereign mRNA facilities in U.K., Canada & Australia) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 31 | +82.4% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 32 | +166.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q2 2025 | Jun 30, 2025 | 17 | – | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 12 | – | Form 10-Q (filed 2026-05-01) ↗ |
Cite this data
StockData. (2026). Moderna Stand-ready manufacturing revenue ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-stand-ready-mfg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.